Pharmarise Holdings Corporation

TSE:2796 Stock Report

Market Cap: JP¥5.5b

Pharmarise Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Masayuki Akiyama

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.5yrs
CEO ownership0.4%
Management average tenureno data
Board average tenure7yrs

Recent management updates

Recent updates

Here's Why Pharmarise Holdings (TSE:2796) Has A Meaningful Debt Burden

Aug 13
Here's Why Pharmarise Holdings (TSE:2796) Has A Meaningful Debt Burden

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 22
Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Mar 07
Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

CEO

Masayuki Akiyama (62 yo)

6.5yrs

Tenure

Mr. Masayuki Akiyama is a President, COO & Representative Director of Pharmarise Holdings Corporation since August 2018 and serves as its Chief Executive Officer. He served as Senior Managing Director of P...


Board Members

NamePositionTenureCompensationOwnership
Masayuki Akiyama
Presidentno datano data0.36%
¥ 19.7m
Keiko Matsuura
Senior MD & Director15.4yrsno data0.39%
¥ 21.2m
Toshimichi Ohno
Chairman of the Board40.7yrsJP¥105.00m29.67%
¥ 1.6b
Sayoko Ohno
Vice Chairman of the Board35.6yrsno data4.06%
¥ 222.6m
Makoto Miura
Auditor1.1yrsno data0.074%
¥ 4.1m
Hiroshi Kanno
Director4.5yrsno data0.081%
¥ 4.5m
Hiromu Tada
Independent External Director8.5yrsno datano data
Yutaka Numata
Director6.5yrsno data0.055%
¥ 3.0m
Tsuneo Sonobe
Independent External Directorless than a yearno datano data
Takayuki Enomoto
Outside Audit & Supervisory Board Member7.4yrsno datano data
Ai Aizawa
Independent External Director1.1yrsno datano data

7.0yrs

Average Tenure

64yo

Average Age

Experienced Board: 2796's board of directors are considered experienced (7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:51
End of Day Share Price 2025/02/07 00:00
Earnings2024/11/30
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmarise Holdings Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.